Abionyx Pharma Sa Stock Fundamentals
| ABNX Stock | EUR 1.24 0.02 1.64% |
Abionyx Pharma SA fundamentals help investors to digest information that contributes to Abionyx Pharma's financial success or failures. It also enables traders to predict the movement of Abionyx Stock. The fundamental analysis module provides a way to measure Abionyx Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abionyx Pharma stock.
Abionyx |
Abionyx Pharma SA Company Current Valuation Analysis
Abionyx Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Abionyx Pharma Current Valuation | 51.58 M |
Most of Abionyx Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abionyx Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Abionyx Pharma SA has a Current Valuation of 51.58 M. This is 99.64% lower than that of the Healthcare sector and 98.89% lower than that of the Biotechnology industry. The current valuation for all France stocks is 99.69% higher than that of the company.
Abionyx Pharma SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Abionyx Pharma's current stock value. Our valuation model uses many indicators to compare Abionyx Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abionyx Pharma competition to find correlations between indicators driving Abionyx Pharma's intrinsic value. More Info.Abionyx Pharma SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Abionyx Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Abionyx Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Abionyx Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abionyx Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abionyx Pharma could also be used in its relative valuation, which is a method of valuing Abionyx Pharma by comparing valuation metrics of similar companies.Abionyx Pharma is currently under evaluation in current valuation category among its peers.
Abionyx Fundamentals
| Return On Equity | -0.92 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 51.58 M | |||
| Shares Outstanding | 28.09 M | |||
| Shares Owned By Insiders | 32.46 % | |||
| Shares Owned By Institutions | 11.99 % | |||
| Price To Earning | 17.78 X | |||
| Price To Book | 5.91 X | |||
| Price To Sales | 15.30 X | |||
| Revenue | 675 K | |||
| Gross Profit | 259 K | |||
| EBITDA | (5.7 M) | |||
| Net Income | (5.82 M) | |||
| Cash And Equivalents | 8.33 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 3.9 M | |||
| Debt To Equity | 0.18 % | |||
| Current Ratio | 2.92 X | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (6.69 M) | |||
| Earnings Per Share | (0.21) X | |||
| Target Price | 5.5 | |||
| Number Of Employees | 62 | |||
| Beta | 0.33 | |||
| Market Capitalization | 52.53 M | |||
| Total Asset | 21.83 M | |||
| Z Score | 7.8 | |||
| Net Asset | 21.83 M |
About Abionyx Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abionyx Pharma SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abionyx Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abionyx Pharma SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France. ABIONYX PHARMA is traded on Paris Stock Exchange in France.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Abionyx Stock
Abionyx Pharma financial ratios help investors to determine whether Abionyx Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abionyx with respect to the benefits of owning Abionyx Pharma security.